Medropharm

Pharmaceutical Cannabinoid & Plant-Based Ingredient Manufacturingmedropharm.ch

Company typePrivate
Founded2014
HeadquartersZürich, Switzerland
Headcount1–10
GTM typeB2B
OfferingHardware or Manufacturing

Medropharm firmographics

Firmographics

Name: Medropharm
Website: https://medropharm.ch
Company type: Private
Founded year: 2014
Operating status: Operating
Headcount range: 1–10 employees
Ownership category
akta.pro rank

Medropharm industry classification

Industry

Product category: Pharmaceutical Cannabinoid & Plant-Based Ingredient Manufacturing
NAICS: Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412)
SIC: Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)
akta.pro primary industry: Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts) (AFAJAKAD)
akta.pro secondary industries: Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Herbal & Botanical Supplements (CRADAGAD)

Keywords

Pharmaceutical-grade cannabinoids
Plant-based extracts
Cannabinoid manufacturing
Botanical active ingredients
Cannabis extraction services

Where Medropharm is headquartered

Location

Headquarters

HQ city: Zürich
HQ country: Switzerland
HQ region: Europe

Markets served

Medropharm business model

Business model

GTM type: B2B
Offering type: Hardware or Manufacturing
Cost components: Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Medropharm product offering

Product offering

Core offering

Medropharm extracts and manufactures pharmaceutical-grade cannabinoid and plant-based products. The company produces active botanical ingredients and intermediates intended for pharmaceutical and medical-product applications, operating a manufacturing model in Switzerland from its Zürich base.

Differentiator

Problem solved

Functional benefit

Products and services

Pharmaceutical-grade cannabinoid and plant-based products Pharmaceutical-grade cannabinoid and plant-based ingredients manufactured by Medropharm, intended for downstream pharmaceutical, medical, or nutraceutical applications. Sold as bulk active ingredients / intermediates rather than finished consumer products.

Companies that use Medropharm

Customer profile

Ideal customer profiles1 record

Medropharm technology and API

Technology

Technology focussed No

API detail

Has API: No
API docs
API detail

Core technology

AI maturity

App detail

Medropharm competitors and assessment

Company assessment

Direct peers

Demecan: German licensed cannabis cultivator and manufacturer producing pharmaceutical-grade flower and extracts for the German medical market; comparable as a vertically integrated cannabinoid pharma-grade producer in Europe.
STENOCARE: Danish producer and distributor of medical cannabis oil and extracts; directly comparable as a European pharmaceutical-grade cannabinoid manufacturer serving regulated patients and prescribers.

Broad incumbents

GW Pharmaceuticals (now part of Jazz Pharmaceuticals): Pioneer of pharmaceutical-grade cannabinoid medicines (e.g., Sativex, Epidiolex); represents the upper-end benchmark for pharmaceutical-grade cannabinoid development and commercialization relevant to Medropharm's positioning.
Aphria / Aurora Cannabis (European footprint): Established Canadian-licensed producers with European GMP facilities supplying medical-grade cannabis flower and extracts; compete with Medropharm for the same European pharmacy and pharma customers.
Canopy Growth Corporation (European operations): Large multi-jurisdiction cannabis producer with established European footprint, including German and Danish facilities; overlaps with Medropharm in pharmaceutical-grade cannabinoid extraction and supply.
Tilray Brands (European medical cannabis division): Global cannabis incumbent with significant medical cannabis operations in Portugal, Germany, and Italy; comparable as a GMP-grade cannabinoid API and finished product supplier into Europe.
Dr. Reddy's Laboratories (cannabinoid / botanical generics): Diversified global pharmaceutical manufacturer active in botanical extracts and cannabinoid-related API development; comparable as a pharmaceutical-grade botanical manufacturer with broader product breadth.

Emerging players

Sanity Group: Berlin-based European medical cannabis and wellness company with cultivation, extraction, and distribution operations; comparable as a mid-sized European player targeting the same regulated API/extract niche.
Cognifi Pharmaceuticals: European specialty cannabinoid developer working on prescription cannabinoid formulations; comparable as a smaller, focused European player operating in the pharmaceutical-grade cannabinoid category.

Regional players

CannMed (formerly Medropharm-supplying Swiss cultivator ecosystem) / Swiss cannabinoid producers: Other Swiss-based licensed producers and extractors operating under Swissmedic oversight and serving cross-border EU demand; comparable by geography, regulatory regime, and product category.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks4 records

Key highlights4 records

Customer concentration

Medropharm financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medropharm leadership team

Management profile

Number of profiles

Medropharm funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medropharm M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medropharm

What does Medropharm do?

When was Medropharm founded?

Medropharm was founded in 2014. It employs 1 to 10 people.

Where is Medropharm based?

Medropharm is headquartered in Zürich, Switzerland, in the Europe region.

Who are Medropharm's main competitors?

Direct peers on record are Demecan and STENOCARE. Broad incumbents are GW Pharmaceuticals (now part of Jazz Pharmaceuticals), Aphria / Aurora Cannabis (European footprint), Canopy Growth Corporation (European operations), Tilray Brands (European medical cannabis division) and Dr. Reddy's Laboratories (cannabinoid / botanical generics). Emerging players are Sanity Group and Cognifi Pharmaceuticals. CannMed (formerly Medropharm-supplying Swiss cultivator ecosystem) / Swiss cannabinoid producers is listed as a regional player.

Does Medropharm have an API?

No public API is recorded for Medropharm.

What industry is Medropharm in?

Medropharm's product category is Pharmaceutical Cannabinoid & Plant-Based Ingredient Manufacturing. Its primary akta.pro industry code is AFAJAKAD, Botanical & Herbal Extracts (Adaptogens, Polyphenols, Essential Oils, Standardized Extracts), with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.